Financials data is unavailable for this security.
View more
Year on year Zeria Pharmaceutical Co Ltd grew revenues 10.74% from 68.38bn to 75.73bn while net income improved 24.78% from 6.20bn to 7.73bn.
| Gross margin | 73.22% |
|---|---|
| Net profit margin | 11.44% |
| Operating margin | 14.05% |
| Return on assets | 6.20% |
|---|---|
| Return on equity | 12.12% |
| Return on investment | 9.82% |
More ▼
Cash flow in JPYView more
In 2024, Zeria Pharmaceutical Co Ltd increased its cash reserves by 15.60%, or 2.51bn. The company earned 12.18bn from its operations for a Cash Flow Margin of 16.09%. In addition the company used 3.95bn on investing activities and also paid 8.12bn in financing cash flows.
| Cash flow per share | 380.64 |
|---|---|
| Price/Cash flow per share | 7.08 |
| Book value per share | 1,858.72 |
|---|---|
| Tangible book value per share | 911.13 |
More ▼
Balance sheet in JPYView more
| Current ratio | 1.11 |
|---|---|
| Quick ratio | 0.8393 |
| Total debt/total equity | 0.542 |
|---|---|
| Total debt/total capital | 0.3508 |
More ▼
Growth rates in JPY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 10.00% and 25.05%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is above the industry average.
| Div yield(5 year avg) | 1.79% |
|---|---|
| Div growth rate (5 year) | 5.29% |
| Payout ratio (TTM) | 21.48% |
| EPS growth(5 years) | 20.32 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 38.80 |
More ▼
